EUFOREA summit sets priorities for allergy and respiratory care research and advocacy
What should doctors prioritize for allergy and asthma care? Experts just met to decide
A summit report outlines research, educational, and advocacy priorities for managing chronic inflammatory respiratory conditions.
Medical experts just aligned on a coordinated plan to improve care for chronic allergies, asthma, and sinus problems over the next two years…
Protocol published for network meta-analysis of first-line treatments in advanced hepatocellular carcinoma
Researchers plan future analysis of first-line liver cancer treatments
This is a protocol for an individual patient data network meta-analysis comparing all first-line regimens for advanced hepatocellular carcin…
A new plan will compare all first-line liver cancer treatments to find which offer the best survival and fewest serious side effects by Marc…
Systematic review links PPARγ to atopic dermatitis pathogenesis and identifies it as a potential therapeutic target
Review suggests a protein target may be linked to eczema and could lead to new treatments
A systematic review synthesizes mechanistic evidence linking peroxisome proliferator-activated receptor gamma (PPARγ) to atopic dermatitis p…
A protein called PPARγ could be a key target for new eczema treatments, as it helps restore skin barrier function and regulate immune respon…
FDA Approves Children's Zyrtec Allergy (cetirizine) for Symptoms of Upper Respiratory Allergies
FDA approves a chewable allergy medicine for children called Children's Zyrtec Allergy
The FDA approved Children's Zyrtec Allergy (cetirizine) for temporarily relieving symptoms of hay fever or other upper respiratory allergies…
FDA approves chewable allergy medicine for kids as young as 2 to help with runny nose, sneezing, and itchy eyes from hay fever.
Qualitative study reveals six themes of patient experience with post-COVID-19 olfactory dysfunction
What's it really like to lose your sense of smell after COVID?
A qualitative study of 20 patients with post-COVID-19 olfactory dysfunction from a Danish otolaryngology department identified six themes de…
Losing the smell of coffee or a child's hair after COVID feels like an invisible disability that changes how people eat, socialize, and see …
Review suggests chemokine inhibition as prospective therapeutic target for atopic dermatitis
Review suggests chemokine pathways may be promising targets for eczema treatment
A review of basic and clinical research in patients with AD and AD model mice found that chemokine ligand-receptor interactions regulate imm…
Blocking specific immune signals in eczema skin reduced inflammation in mice, suggesting a new treatment path as human trials progress.
Allergen-antibody complexes activate human neutrophils via FcγR-independent phagocytosis in lab study
Lab study explores how immune cells react to pollen allergen complexes
A laboratory study using neutrophils from birch pollen allergic and non-allergic donors found that allergen-antibody immune complexes (AICs)…
Lab tests show modified pollen complexes help immune cells present allergens better, while standard versions trigger DNA webs that might blo…
VALIANT: Phase 2 trial of verekitug (UPB-101) for severe asthma completes enrollment of 479 patients
Can a new injection help people with severe asthma breathe easier and avoid dangerous flare-ups?
The VALIANT study, a phase 2 trial, evaluated the efficacy and safety of subcutaneous verekitug (UPB-101) versus placebo in adults with seve…
A new asthma injection aims to reduce dangerous flare-ups and improve breathing for adults with severe asthma in a completed trial.
Pink vs. white inhaler actuators studied for asthma symptom perception in crossover trial
Study compares pink and white asthma inhalers for how patients perceive symptoms
A phase IIIb randomized, double-blind, crossover trial in 78 adults with moderate to severe asthma compared identical beclomethasone/formote…
Asthma patients tried identical inhalers in pink or white to see if color changed how they perceived their symptoms and which device they pr…
Phase 2 trial tests amlitelimab add-on therapy in adults with moderate-to-severe asthma
Phase 2 trial tests new asthma drug amlitelimab in adults with moderate-to-severe asthma
A phase 2 randomized controlled trial enrolled 437 adults with moderate-to-severe asthma globally to evaluate amlitelimab versus placebo.
A new asthma drug called amlitelimab is being tested to see if adding it to current treatments can reduce severe asthma attacks in adults wi…
Digital albuterol system feasibility studied in 333 asthma patients with suboptimal control
Can a smart inhaler help people with uncontrolled asthma breathe easier?
A phase 4, open-label, multicenter feasibility study randomized 333 participants aged 13+ with suboptimal asthma control to either the Albut…
A new smart inhaler system tested for 12 weeks to see if it helps people with uncontrolled asthma breathe easier, but results are not yet av…
Phase 4 trial compares LPV/r plus raltegravir versus LPV/r plus N(t)RTIs for HIV after first-line failure
Study compares two HIV treatment strategies after first-line therapy fails
A phase 4 randomized controlled trial enrolled 558 HIV-infected subjects who had virologically failed first-line NNRTI-based therapy.
A completed Phase 4 trial compared two HIV treatment strategies after first-line therapy fails, but results for viral suppression and safety…